Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06079346 · ClinicalTrials.gov registry record · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by Oncotelic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
- 2
- Study locations
NCT06079346 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Oncotelic. The registered enrollment target is 455 participants, below the 595-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (24% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06079346, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Oncotelic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG mFOLFIRINOX
- DRUG OT-101
Study Locations (2)
Michigan
- Karmanos Cancer Center - Detroit
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06079346
The ClinicalTrials.gov registry entry for NCT06079346 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 595-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (24% lower). The listed sponsor is Oncotelic, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which mFOLFIRINOX is the first listed.
NCT06079346 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT06079346 about?
NCT06079346 is a clinical study titled "A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer". The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.
What is the current status of trial NCT06079346?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2024-05-01. Estimated completion is 2027-06-01.
What conditions does trial NCT06079346 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06079346?
The interventions under investigation include: mFOLFIRINOX (DRUG), OT-101 (DRUG).
Who is sponsoring clinical trial NCT06079346?
This trial is sponsored by Oncotelic, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06079346 being conducted?
This trial has 2 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
-
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.